Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Phase I Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers

Trial Profile

Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Phase I Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cidofovir (Primary) ; Carboplatin
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Nov 2014 Results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 22 Jun 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Jul 2009).
    • 22 Jun 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Jul 2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top